Openbookopenbook
Equity
Tristel(TSTL)
GBX --+0.00%
Reward75High
Risk13Low
📊75%Data
Revenue growing 14% YoY
TSTL
+0.0 · +0.00%
GBX · LSE
Tristel | Healthcare
Quality Compounder
Market Cap:182.14M
ℹ️
Reward Rating
75
High
Top 10% (model universe)
75% data coverage
ℹ️
Risk Rating
13
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on TSTL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 473p.

What is Tristel?

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally.

TSTL · Verdict

Strong reward · low risk

TSTL scores well on profitability and volatility with no major weaknesses flagged in the model.

Based on 88% data coverage

TSTL · Verdict

What’s working & what to watch

Strengths 6

  • Profitability97/100

    14% net margin · 20% ROE

  • Volatility95/100

    Top decile vs peers

  • Balance sheet92/100

    Interest covered 33.5×

  • Cash flow91/100

    20% free-cash-flow margin

  • Growth84/100

    Rev +14.3% CAGR · earnings +88.8%

  • Valuation66/100

    P/E 20.5× · PEG 1.18

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Tristel?

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 182.14M, and a P/E ratio of 27.1x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (75)

The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap182.14M
P/E Ratio27.1429
Dividend YieldN/A
52 Week High445
52 Week Low253.8467
Last AnnualJune
IPO Date6/1/2005
IncorporatedUK
Shares Outstanding48M
No. of Employees267
IndustryMedical Instruments & Supplies
ExchangeLSE
Beta0.249
CurrencyGBX · Reports in GBP
Websitetristel.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.